Related Experiment Videos
Calcium-channel blockers and anaesthesia.
P G Durand1, J J Lehot, P Foëx
1Department of Anaesthesia and Intensive Care, Hôpital Cardio-vasculaire et Pneumologique, Lyon, France.
Canadian Journal of Anaesthesia = Journal Canadien D'Anesthesie
|January 1, 1991
Summary
Verapamil, the first calcium-channel blocker (CCB), offers antiarrhythmic and vasodilator effects. Anesthetists must understand CCB perioperative management and drug interactions for safe patient care.
Area of Science:
- Cardiovascular Pharmacology
- Anesthesiology
Background:
- Verapamil, the inaugural calcium-channel blocker (CCB), has been utilized since 1962.
- CCBs are now prominent cardiovascular therapeutics with established mechanisms and indications.
Purpose of the Study:
- To inform anesthesiologists about perioperative considerations for patients on CCBs.
- To detail drug interactions between CCBs and anesthetic agents.
Main Methods:
- Review of experimental and clinical studies on CCB pharmacology.
- Analysis of perioperative management strategies for CCB patients.
Main Results:
- CCBs possess antiarrhythmic and coronary vasodilator properties.
- Understanding CCB interactions with anesthetics is crucial for patient safety.
Conclusions:
- Anesthetists require comprehensive knowledge of CCB use, interactions, and perioperative challenges.
- Safe management of CCB patients necessitates awareness of drug-specific effects and anesthetic implications.